X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the divestment, Mundipharma received the rights for Rezzayo (rezafungin acetate), an echinocandin antifungal, approved for the treatment of invasive candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mundipharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment April 24, 2024
Details:
Cidara has regained exclusive global development and commercial rights for CD388, which is under development for preventing all strains of influenza A and B.
Lead Product(s): CD388
Therapeutic Area: Infections and Infectious Diseases Product Name: CD388
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 24, 2024
Details:
The net gross proceeds will be utilized to finance the clinical advancement of CD388, currently undergoing mid-stage clinical trials with patients for treating influenza.
Lead Product(s): CD388
Therapeutic Area: Infections and Infectious Diseases Product Name: CD388
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 24, 2024
Details:
The payment triggered under the agreement is following the European approval of Rezzayo (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Mundipharma
Deal Size: $568.0 million Upfront Cash: $39.0 million
Deal Type: Partnership February 12, 2024
Details:
Rezzayo (rezafungin acetate) is a novel once-weekly echinocandin antifungal approved by USFDA. It is now approved by MHRA for the treatment of invasive candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Rezzayo (rezafungin) is an echinocandin antifungal that helps to inhibit the synthesis of 1,3-beta-D-glucan, an essential component of fungal cell walls. It recently got EU approval for the treatment of invasive candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
Rezzayo (rezafungin acetate) is a novel once-weekly echinocandin and 1,3-beta-glucan synthase inhibitor. It is approved for the treatment for Invasive Candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Mundipharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
Under the agreement, Cidara is studying CD388, a second generation, anti-viral Fc conjugate (AVC), in Phase 1 and 2a clinical trials evaluating safety and pharmacokinetics as well as efficacy as pre-exposure prophylaxis against an influenza virus.
Lead Product(s): CD388
Therapeutic Area: Infections and Infectious Diseases Product Name: CD388
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $780.0 million Upfront Cash: $27.0 million
Deal Type: Licensing Agreement September 06, 2023
Details:
Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
